210 related articles for article (PubMed ID: 35924778)
1. Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
Luo S; Vasbinder A; Du-Fay-de-Lavallaz JM; Gomez JMD; Suboc T; Anderson E; Tekumulla A; Shadid H; Berlin H; Pan M; Azam TU; Khaleel I; Padalia K; Meloche C; O'Hayer P; Catalan T; Blakely P; Launius C; Amadi KM; Pop-Busui R; Loosen SH; Chalkias A; Tacke F; Giamarellos-Bourboulis EJ; Altintas I; Eugen-Olsen J; Williams KA; Volgman AS; Reiser J; Hayek SS;
J Am Heart Assoc; 2022 Sep; 11(18):e025198. PubMed ID: 35924778
[TBL] [Abstract][Full Text] [Related]
2. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism.
Engström G; Zöller B; Svensson PJ; Melander O; Persson M
Thromb Haemost; 2016 Mar; 115(3):657-62. PubMed ID: 26466866
[TBL] [Abstract][Full Text] [Related]
3. Circulating Soluble Urokinase Plasminogen Activator Receptor as a Predictive Indicator for COVID-19-Associated Acute Kidney Injury and Mortality: Clinical and Bioinformatics Analysis.
Abdellatif HAA; Sultan BO; Nassar HM; Gomaa MEE; Sakr MG; Riad E; Al-Harbi AI; Abdulhakim JA; Fawzy MS; Abd El-Fadeal NM
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108340
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.
Azam TU; Shadid HR; Blakely P; O'Hayer P; Berlin H; Pan M; Zhao P; Zhao L; Pennathur S; Pop-Busui R; Altintas I; Tingleff J; Stauning MA; Andersen O; Adami ME; Solomonidi N; Tsilika M; Tober-Lau P; Arnaoutoglou E; Keitel V; Tacke F; Chalkias A; Loosen SH; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Reiser J; Hayek SS;
J Am Soc Nephrol; 2020 Nov; 31(11):2725-2735. PubMed ID: 32963090
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.
Padelli M; Gueye P; Guilloux D; Banydeen R; Campana V; Cabie A; Neviere R
Biomark Med; 2022 Feb; 16(3):169-177. PubMed ID: 35081737
[TBL] [Abstract][Full Text] [Related]
6. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study.
Oulhaj A; Alsuwaidi AR; Suliman A; Gasmelseed H; Khan S; Alawi S; Hukan Y; George J; Alshamsi F; Sheikh F; Babiker ZOE; Prattes J; Sourij H
Int J Infect Dis; 2021 Jun; 107():188-194. PubMed ID: 33862208
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients.
Hojker M; Tršan J; Tršan U; Gale A; Jerman A; Košuta D
Clin Hemorheol Microcirc; 2023; 83(4):387-395. PubMed ID: 36683498
[TBL] [Abstract][Full Text] [Related]
8. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
Segala FV; Rando E; Salvati F; Negri M; Catania F; Sanmartin F; Murri R; Giamarellos-Bourboulis EJ; Fantoni M
PLoS One; 2023; 18(4):e0273202. PubMed ID: 37014833
[TBL] [Abstract][Full Text] [Related]
9. Soluble urokinase Plasminogen Activator Receptor (suPAR) mediates the effect of a lower education level on adverse outcomes in patients with coronary artery disease.
Füller D; Liu C; Ko YA; Alkhoder AA; Desai SR; Almuwaqqat Z; Patel SA; Ejaz K; Kauser T; Martini MA; Alvi Z; Mehta PK; Sperling LS; Quyyumi AA
Eur J Prev Cardiol; 2024 Mar; 31(5):521-528. PubMed ID: 37788634
[TBL] [Abstract][Full Text] [Related]
10. SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
Vasbinder A; Padalia K; Pizzo I; Machado K; Catalan T; Presswalla F; Anderson E; Ismail A; Hutten C; Huang Y; Blakely P; Azam TU; Berlin H; Feroze R; Launius C; Meloche C; Michaud E; O'Hayer P; Pan M; Shadid HR; Rasmussen LJH; Roberts DA; Zhao L; Banerjee M; Murthy V; Loosen SH; Chalkias A; Tacke F; Reiser J; Giamarellos-Bourboulis EJ; Eugen-Olsen J; Pop-Busui R; Hayek SS;
J Med Virol; 2024 Jan; 96(1):e29389. PubMed ID: 38235904
[TBL] [Abstract][Full Text] [Related]
11. Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019.
Thondapu V; Montes D; Rosovsky R; Dua A; McDermott S; Lu MT; Ghoshhajra B; Hoffmann U; Gerhard-Herman MD; Hedgire S
J Vasc Surg Venous Lymphat Disord; 2021 Jul; 9(4):835-844.e4. PubMed ID: 33188961
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker in COVID-19 patients: a systematic review.
Lobato-Martínez E; Sanchez-Martinez R; de-Miguel Balsa E; Ramos-Rincon JM
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):852-860. PubMed ID: 38305628
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019.
Liu Y; Cai J; Wang C; Jin J; Qu L
J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1099-1111.e6. PubMed ID: 33529719
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor (suPAR) predicts critical illness and kidney failure in patients admitted to the intensive care unit.
Reisinger AC; Niedrist T; Posch F; Hatzl S; Hackl G; Prattes J; Schilcher G; Meißl AM; Raggam RB; Herrmann M; Eller P
Sci Rep; 2021 Sep; 11(1):17476. PubMed ID: 34471146
[TBL] [Abstract][Full Text] [Related]
15. Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery (SPARSE).
Chalkias A; Laou E; Kolonia K; Ragias D; Angelopoulou Z; Mitsiouli E; Kallemose T; Smith-Hansen L; Eugen-Olsen J; Arnaoutoglou E
Surgery; 2022 Jun; 171(6):1619-1625. PubMed ID: 34736789
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
[TBL] [Abstract][Full Text] [Related]
17. Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High-Sensitivity C-Reactive Protein.
Hayek SS; Divers J; Raad M; Xu J; Bowden DW; Tracy M; Reiser J; Freedman BI
J Am Heart Assoc; 2018 May; 7(9):. PubMed ID: 29716888
[TBL] [Abstract][Full Text] [Related]
18. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.
Liao TH; Wu HC; Liao MT; Hu WC; Tsai KW; Lin CC; Lu KC
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142634
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.
Törnkvist PBS; Haupt TH; Rasmussen LJH; Ladelund S; Toft U; Pisinger C; Eugen-Olsen J
Br J Nutr; 2019 Mar; 121(6):699-708. PubMed ID: 30626457
[TBL] [Abstract][Full Text] [Related]
20. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
